Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

NCT07432958 is registered in ClinicalTrials.gov with Appello Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07432958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07432958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Lead sponsor
Appello Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
February 25, 2026
Completion date
January 3, 2028
Enrollment
150 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease